Glutamine Synthetase Is a Genetic Determinant of Cell Type–Specific Glutamine Independence in Breast Epithelia

English version České info

Although significant variations in the metabolic profiles exist among different cells, little is understood in terms of genetic regulations of such cell type–specific metabolic phenotypes and nutrient requirements. While many cancer cells depend on exogenous glutamine for survival to justify the therapeutic targeting of glutamine metabolism, the mechanisms of glutamine dependence and likely response and resistance of such glutamine-targeting strategies among cancers are largely unknown. In this study, we have found a systematic variation in the glutamine dependence among breast tumor subtypes associated with mammary differentiation: basal- but not luminal-type breast cells are more glutamine-dependent and may be susceptible to glutamine-targeting therapeutics. Glutamine independence of luminal-type cells is associated mechanistically with lineage-specific expression of glutamine synthetase (GS). Luminal cells can also rescue basal cells in co-culture without glutamine, indicating a potential for glutamine symbiosis within breast ducts. The luminal-specific expression of GS is directly induced by GATA3 and represses glutaminase expression. Such distinct glutamine dependency and metabolic symbiosis is coupled with the acquisition of the GS and glutamine independence during the mammary differentiation program. Understanding the genetic circuitry governing distinct metabolic patterns is relevant to many symbiotic relationships among different cells and organisms. In addition, the ability of GS to predict patterns of glutamine metabolism and dependency among tumors is also crucial in the rational design and application of glutamine and other metabolic pathway targeted therapies.

Vyšlo v časopise: Glutamine Synthetase Is a Genetic Determinant of Cell Type–Specific Glutamine Independence in Breast Epithelia. PLoS Genet 7(8): e32767. doi:10.1371/journal.pgen.1002229
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1002229

Souhrn

Zdroje

1. ChangHYChiJTDudoitSBondreCvan de RijnM 2002 Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci U S A 99 12877 12882

2. ChiJTChangHYHaraldsenGJahnsenFLTroyanskayaOG 2003 Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci U S A 100 10623 10628

3. ChiJTRodriguezEHWangZNuytenDSMukherjeeS 2007 Gene expression programs of human smooth muscle cells: tissue-specific differentiation and prognostic significance in breast cancers. PLoS Genet 3 e164 doi:10.1371/journal.pgen.0030164

4. PerouCMSorlieTEisenMBvan de RijnMJeffreySS 2000 Molecular portraits of human breast tumours. Nature 406 747 752

5. SorlieTPerouCMTibshiraniRAasTGeislerS 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98 10869 10874

6. DairkeeSHPuettLHackettAJ 1988 Expression of basal and luminal epithelium-specific keratins in normal, benign, and malignant breast tissue. J Natl Cancer Inst 80 691 695

7. LimEVaillantFWuDForrestNCPalB 2009 Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15 907 913

8. RossDTPerouCM 2001 A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines. Dis Markers 17 99 109

9. GatzaMLLucasJEBarryWTKimJWWangQ 2010 A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A 107 6994 6999

10. LacroixMLeclercqG 2004 Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 83 249 289

11. Charafe-JauffretEGinestierCMonvilleFFinettiPAdelaideJ 2006 Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25 2273 2284

12. HuperGMarksJR 2007 Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation. Cancer Res 67 2990 3001

13. GatzaMLKungHNBlackwellKLDewhirstMWMarksJR 2011 Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Res 13 R62

14. Yalcin-OzuysalOBriskenC 2009 From normal cell types to malignant phenotypes. Breast Cancer Res 11 306

15. VisvaderJE 2009 Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev 23 2563 2577

16. HsuPPSabatiniDM 2008 Cancer cell metabolism: Warburg and beyond. Cell 134 703 707

17. TennantDADuranRVGottliebE 2010 Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10 267 277

18. WarburgO 1956 On respiratory impairment in cancer cells. Science 124 269 270

19. VaupelP 2004 Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14 198 206

20. ClavellLAGelberRDCohenHJHitchcock-BryanSCassadyJR 1986 Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 315 657 663

21. DeBerardinisRJChengT 2010 Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29 313 324

22. WiseDRThompsonCB 2010 Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci

23. YunevaMZamboniNOefnerPSachidanandamRLazebnikY 2007 Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 178 93 105

24. WiseDRDeBerardinisRJMancusoASayedNZhangXY 2008 Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A 105 18782 18787

25. GaoPTchernyshyovIChangTCLeeYSKitaK 2009 c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458 762 765

26. YangCSudderthJDangTBachooRMMcDonaldJG 2009 Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res 69 7986 7993

27. WangJBEricksonJWFujiRRamachandranSGaoP 2010 Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18 207 219

28. CurthoysNPWatfordM 1995 Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr 15 133 159

29. KaadigeMRLooperREKamalanaadhanSAyerDE 2009 Glutamine-dependent anapleurosis dictates glucose uptake and cell growth by regulating MondoA transcriptional activity. Proc Natl Acad Sci U S A

30. NewsholmePProcopioJLimaMMPithon-CuriTCCuriR 2003 Glutamine and glutamate—their central role in cell metabolism and function. Cell Biochem Funct 21 1 9

31. KilbergMSPanYXChenHLeung-PinedaV 2005 Nutritional control of gene expression: how mammalian cells respond to amino acid limitation. Annu Rev Nutr 25 59 85

32. DongJQiuHGarcia-BarrioMAndersonJHinnebuschAG 2000 Uncharged tRNA activates GCN2 by displacing the protein kinase moiety from a bipartite tRNA-binding domain. Mol Cell 6 269 279

33. HardingHPZhangYZengHNovoaILuPD 2003 An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 11 619 633

34. NeveRMChinKFridlyandJYehJBaehnerFL 2006 A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10 515 527

35. ChinKDeVriesSFridlyandJSpellmanPTRoydasguptaR 2006 Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10 529 541

36. DeMarcoVDyessKStraussDWestCMNeuJ 1999 Inhibition of glutamine synthetase decreases proliferation of cultured rat intestinal epithelial cells. J Nutr 129 57 62

37. Asselin-LabatMLSutherlandKDBarkerHThomasRShackletonM 2007 Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 9 201 209

38. Kouros-MehrHSlorachEMSternlichtMDWerbZ 2006 GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127 1041 1055

39. Kouros-MehrHBechisSKSlorachEMLittlepageLEEgebladM 2008 GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13 141 152

40. EeckhouteJKeetonEKLupienMKrumSACarrollJS 2007 Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res 67 6477 6483

41. KilbergMSShanJSuN 2009 ATF4-dependent transcription mediates signaling of amino acid limitation. Trends Endocrinol Metab 20 436 443

42. ChenJLLucasJESchroederTMoriSWuJ 2008 The genomic analysis of lactic acidosis and acidosis response in human cancers. PLoS Genet 4 e1000293 doi:10.1371/journal.pgen.1000293

43. ChenJLMerlDPetersonCWWuJLiuPY 2010 Lactic acidosis triggers starvation response with paradoxical induction of TXNIP through MondoA. PLoS Genet 6 e1001093 doi:10.1371/journal.pgen.1001093

44. ChiJTRodriguezEHWangZNuytenDSAMukherjeeS 2007 Gene Expression Programs of Human Smooth Muscle Cells: Tissue-Specific Differentiation and Prognostic Significance in Breast Cancers. PLoS Genet 3 e164 doi:10.1371/journal.pgen.0030164

45. ShanJLopezMCBakerHVKilbergMS 2010 Expression profiling after activation of the amino acid deprivation response in HepG2 human hepatoma cells. Physiol Genomics

46. BildAHYaoGChangJTWangQPottiA 2006 Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439 353 357

47. ThornburgJMNelsonKKClemBFLaneANArumugamS 2008 Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res 10 R84

48. TodorovaVKKaufmannYLuoSSuzanne KlimbergV 2010 Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake. Cancer Chemother Pharmacol

49. ChangTHSzaboE 2000 Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 60 1129 1138

50. LiZBaoSWuQWangHEylerC 2009 Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15 501 513

51. GrushkoTADignamJJDasSBlackwoodAMPerouCM 2004 MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res 10 499 507

52. BildAHParkerJSGustafsonAMAcharyaCRHoadleyKA 2009 An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Res 11 R55

53. HuWZhangCWuRSunYLevineA 2010 Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A 107 7455 7460

54. SuzukiSTanakaTPoyurovskyMVNaganoHMayamaT 2010 Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci U S A 107 7461 7466

55. Martinez-HernandezABellKPNorenbergMD 1977 Glutamine synthetase: glial localization in brain. Science 195 1356 1358

56. BrosnanMEBrosnanJT 2009 Hepatic glutamate metabolism: a tale of 2 hepatocytes. Am J Clin Nutr 90 857S 861S

57. BurchHBChoiSMcCarthyWZWongPYLowryOH 1978 The location of glutamine synthetase within the rat and rabbit nephron. Biochem Biophys Res Commun 82 498 505

58. MylonaPPawlowskiKBisselingT 1995 Symbiotic Nitrogen Fixation. Plant Cell 7 869 885

59. DouglasAE 1998 Nutritional interactions in insect-microbial symbioses: aphids and their symbiotic bacteria Buchnera. Annu Rev Entomol 43 17 37

60. DaikhinYYudkoffM 2000 Compartmentation of brain glutamate metabolism in neurons and glia. J Nutr 130 1026S 1031S

61. EngCHYuKLucasJWhiteEAbrahamRT 2010 Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. Sci Signal 3 ra31

62. VermeulenTGorgBVoglTWolfMVargaG 2008 Glutamine synthetase is essential for proliferation of fetal skin fibroblasts. Archives of Biochemistry and Biophysics 478 96 102

63. GrasGPorcherayFSarnahBLeoneC 2006 The glutamate-glutamine cycle as an inducible, protective face of macrophage activation. Journal of Leukocyte Biology 80 1067 1075

64. TarditoSUggeriJBozzettiCBianchiMGRotoliBM 2007 The inhibition of glutamine synthetase sensitizes human sarcoma cells to L-asparaginase. Cancer Chemother Pharmacol 60 751 758

65. SreekumarAPoissonLMRajendiranTMKhanAPCaoQ 2009 Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457 910 914

66. DangLWhiteDWGrossSBennettBDBittingerMA 2010 Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 465 966